Market Signal Briefing

SelectQuote, Inc. (SLQT) Q1 2026 Earnings Call November 6, 2025 8:30 AM EST

Company Participants

Matthew Gunter
Timothy Danker - CEO & Director
Ryan Clement - Chief Financial Officer
William Grant - Chief Operating Officer

Conference Call Participants

Michael Murray - RBC Capital Markets, Research Division
Patrick McCann - NOBLE Capital Markets, Inc., Research Division

Presentation

Operator

Welcome to SelectQuote's First Quarter Earnings Conference Call. [Operator Instructions] It is now my pleasure to introduce Matt Gunter, SelectQuote Investor Relations. Mr. Gunter, you may begin the conference.

Matthew Gunter

Thank you, and good morning, everyone. Welcome to SelectQuote's fiscal first quarter earnings call. Before we begin our call, I would like to mention that on our website, we have provided a slide presentation to help guide our discussion. After today's call, a replay will also be available on our website.

Joining me from the company, I have our Chief Executive Officer, Tim Danker; and Chief Financial Officer, Ryan Clement. Following Tim and Ryan's comments today, we will have a question-and-answer session.

As referenced on Slide 2, during this call, we will be discussing some non-GAAP financial measures. The most directly comparable GAAP financial measures and a reconciliation of the differences between the GAAP and the non-GAAP financial measures are available in our earnings release and investor presentation on our website.

And finally, a reminder that certain statements made today may be forward-looking statements. These statements are made based upon management's current expectations and beliefs concerning future events impacting the company, and therefore, involve a number of uncertainties and risks, including, but not limited to, those described in our earnings release, annual report on Form 10-K for the period ended June 30, 2025, and subsequent filings with the SEC. Therefore, the actual results of operations or financial condition of the company could differ materially from those expressed or implied in our forward-looking statements.

Recommended For You

SalMar ASA (OTCPK:SALRY) Q3 2025 Earnings Call November 6, 2025 9:15 AM EST

Company Participants

Frode Arntsen - President & CEO
Ulrik Steinvik - Chief Financial Officer

Presentation

Frode Arntsen
President & CEO

Welcome to the presentation of SalMar's results for the third quarter of 2025. My name is Frode Arntsen, and I am the CEO. And joining me today is our CFO, Ulrik Steinvik.

I have said before that SalMar, it's a job 24 hours a day, 360 days a year. When we say we produce salmon on the salmon terms, this has really been as true as now in the third quarter. The record high harvest volume and activity level we've had this quarter have meant that employees across the entire value chain have been working day and night to ensure we carry out the necessary lice treatments, the farming sites are ready when the whale boat arrives, that the processing plants are ready when the fish is to be harvested and that we are able to sell and ship to our products to all corners of the world.

I want to say a big thank you to all our employees who have worked day and night through the quarter. You are the team that makes it possible for us to present financial results today that we are more satisfied with than the last quarter, even though salmon prices have been lower. At the same time, you are also laying the foundation for us to increase volumes further into 2026 and reduce cost levels going forward.

Today's review will follow the same sequence as before. I will take you through some highlights as well as the segments. Then CFO, Ulrik, will guide you through the financial update. Finally, I will focus on volume for '26 and new units for post-smolt production at sea. In total for Norway, we

Recommended For You

Nvidia CEO Jensen Huang is warning that China will overtake America in the global artificial intelligence (AI) race.

The chipmaker's chief executive said the West is limiting its own progress in AI through excessive "cynicism," while pointing to China's lower energy costs and fewer regulatory hurdles as advantages, he told the Financial Times on Wednesday on the sidelines of the newspaper's Future of AI Summit.

"China is going to win the AI race," Huang said.

NVIDIA LEADS AMERICA’S AI 'INDUSTRIAL REVOLUTION' WITH MAJOR MANUFACTURING MOVE

Nvidia CEO Jensen Huang introduces an "Industrial AI Cloud" project during a press conference in Berlin, Germany, on Nov. 4, 2025. (REUTERS/Lisi Niesner / Reuters)

NVIDIA TO INVEST UP TO $100B IN OPENAI

Huang also criticized new AI rules by states across the U.S. that could lead to greater regulations. He compared this to China’s energy subsidies, which lower costs for companies using Chinese AI chips, according to the Financial Times.

In a statement posted to X on Wednesday, Huang added that "China is nanoseconds behind America in AI."

"It's vital that America wins by racing ahead and winning developers worldwide," Huang said, according to Reuters.

Nvidia's headquarters in Santa Clara, California, on Feb. 15, 2024. (Photographer: Michaela Vatcheva/Bloomberg via Getty Images)

The chief executive has previously cautioned that U.S. AI models are not far ahead of China’s and has called for broader access to Nvidia chips globally, the Financial Times reported.

His comments Wednesday follow after President Donald Trump recently maintained a ban on Nvidia’s most advanced AI chips being sold to China, according to the Financial Times.

NVIDIA CEO TOUTS NEW AI 'INDUSTRIAL REVOLUTION,' PRAISES TRUMP TARIFFS FOR ROLE IN CHIP PRODUCTION

U.S. President Donald Trump greets Chinese President Xi Jinping ahead of a bilateral meeting at Gimhae Air Base on Oct. 30, 2025, in Busan, South Korea.  (Andrew Harnik/Getty Images)

In an interview that aired Sunday on CBS’ "60 Minutes" and in comments to reporters aboard Air Force One, Trump said Nvidia’s most powerful Blackwell chips should be reserved exclusively for U.S. customers, according to Reuters.

Ticker Security Last Change Change % NVDA NVIDIA CORP. 189.67 -5.54
-2.84%
"The most advanced, we will not let anybody have them other than the United States," Trump told CBS.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Last week, Nvidia also became the first company in history to reach a $5 trillion market valuation.

Nvidia did not immediately respond to FOX Business' request for comment.

Q3: 2025-11-05 Earnings SummaryEPS of $0.66 beats by $0.00

 |

Revenue of

$197.13M

(17.32% Y/Y)

beats by $3.16M

U.S. Physical Therapy, Inc. (USPH) Q3 2025 Earnings Call November 6, 2025 10:30 AM EST

Company Participants

Christopher Reading - CEO & Chairman
Jason Curtis
Carey Hendrickson - Chief Financial Officer
Eric Williams - President & COO

Conference Call Participants

Brian Tanquilut - Jefferies LLC, Research Division
Benjamin Rossi - JPMorgan Chase & Co, Research Division
Joanna Gajuk - BofA Securities, Research Division
Lawrence Solow - CJS Securities, Inc.
Constantine Davides - Citizens JMP Securities, LLC, Research Division
Michael Petusky - Barrington Research Associates, Inc., Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the U.S. Physical Therapy Third Quarter 2025 and Full Year Earnings Conference Call. [Operator Instructions] Please be advised that today's call is being recorded. [Operator Instructions]

I'd now like to turn the call over to Chris Reading, Chairman and CEO. Please go ahead, sir.

Christopher Reading
CEO & Chairman

Thank you. Good morning, and welcome, everyone, to U.S. Physical Therapy's third quarter 2025 earnings call. We've got a few of our executive team on the line with me this morning, including Carey Hendrickson, our Chief Financial Officer; Eric Williams, our President and COO of East; Rick Binstein, our Executive VP and General Counsel; Jason Curtis, our Senior Vice President of Accounting and Treasury.

Before we begin to discuss our quarter and our year-to-date performance, I know we need to cover a brief disclosure. So Jason, if you would, please.

Jason Curtis

Thank you, Chris. The presentation includes forward-looking statements, which involve certain risks and uncertainties. These forward-looking statements are based on the company's current views and assumptions.

The company's actual results may vary materially from those anticipated. Please see the company's filings with the Securities and Exchange Commission for more information.

This presentation also includes certain non-GAAP measures as defined in Regulation G and the related

Recommended For You

Thermon Group Holdings, Inc. (THR) Q2 2026 Earnings Call November 6, 2025 11:00 AM EST

Company Participants

Ivonne Salem - Vice President of FP&A and Investor Relations
Bruce Thames - President, CEO & Director
Thomas Cerovski - Senior VP & COO
Jan Schott - Senior VP & CFO

Conference Call Participants

Justin Ages - CJS Securities, Inc.
Brian Drab - William Blair & Company L.L.C., Research Division
Alfred Moore - ROTH Capital Partners, LLC, Research Division

Presentation

Operator

Greetings, and welcome to the Thermon Earnings conference call fiscal year 2026 quarter 2. [Operator Instructions] As a reminder, this conference is being recorded.

And it is now my pleasure to introduce to you, Ivonne Salem, Vice President of FP&A and Investor Relations. Thank you, Ivonne. You may begin.

Ivonne Salem
Vice President of FP&A and Investor Relations

Good morning, and thank you for joining Thermon Group's Second Quarter Fiscal 2026 Results Conference Call. Leading the call today are CEO, Bruce Thames; Chief Financial Officer, Jan Schott; and Chief Operating Officer, Tom Cerovski. Earlier this morning, we issued an earnings press release, which has been filed with the SEC on Form 8-K and is also available on the Investor Relations section of our website. Additionally, the slides for this conference call can be found in our IR website under News & Events, IR Calendar, Earnings Conference Call Q2 2026.

During the call, we will discuss some items that do not conform to generally accepted accounting principles. We have reconciled those items to the most comparable GAAP measures in the tables at the end of the earnings press release. These non-GAAP measures should be considered in addition to and not as a substitute for measures of financial performance reported in accordance with GAAP. I would like to remind you that during this call, we might make certain forward-looking statements regarding our

Recommended For You

The catalyst was Upwork's third-quarter earnings report, which provided clear evidence that its strategic transformation is not just underway but is delivering substantial financial results.

SummaryApple Inc. guided to its best iPhone quarter ever: double-digit iPhone growth and 47–48% gross margins.iPhone 17 is tracking 14% above iPhone 16 in the first 10 days, skewed to Pro, with China sales improving and management expecting a Q1 return to growth.I model AAPL's FQ1 iPhone revenue at $76.05–$77.44B, yielding $36.13–$37.94B in gross profit, assuming 47.5–49% GM; each extra 1M Pro/Pro Max units adds about $1.1B to revenue.In my view, Black Friday/Cyber Week will be accretive to sales, but heavier U.S. carrier promos (e.g., AT&T) could compress margins. Keep an eye on U.S. carrier websites.Overall, I reiterate my Strong Buy rating for AAPL, as I see a big overhang (i.e., the impact of the delay of AI-enhanced Siri) removed from the stock. Nikada/iStock Unreleased via Getty Images

In my last coverage on Apple Inc. (AAPL), I stuck my neck out and predicted $260B before year-end. To be honest, I didn't anticipate shares reaching my price target so quickly.

In the last

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of KBR, Inc. (NYSE: KBR) between May 6, 2025 and June 19, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

So what: If you purchased KBR securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the KBR class action, go to https://rosenlegal.com/submit-form/?case_id=42136 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) despite the knowledge that the U.S. Department of Defense's Transportation Command (TRANSCOM) had, for months, had material concerns with HomeSafe's ability to fulfill the Global Household Goods Contract, defendants claimed that the partnership was without issue, and would ramp up in future quarters; and (2) as a result, defendants' statements about KBR's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the KBR class action, go to https://rosenlegal.com/submit-form/?case_id=42136 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Altice USA, Inc. (ATUS) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST

Company Participants

Sarah Freedman - Investor Relations Officer
Dennis Mathew - CEO & Chairman
Marc Sirota - Chief Financial Officer

Conference Call Participants

Kutgun Maral - Evercore ISI Institutional Equities, Research Division
Vikash Harlalka - New Street Research LLP
Robert Palmisano - Raymond James & Associates, Inc., Research Division
Craig Moffett - MoffettNathanson LLC
Sebastiano Petti - JPMorgan Chase & Co, Research Division
Samuel McHugh - BNP Paribas, Research Division

Presentation

Operator

Greetings, and welcome to the Altice USA Third Quarter 2025 Earnings Results. [Operator Instructions]

It is now my pleasure to introduce your host, Sarah Freedman, Vice President of Investor Relations. Thank you. You may begin.

Sarah Freedman
Investor Relations Officer

Thank you. Welcome to the Altice USA Q3 2025 Earnings Call. We are joined today by Altice USA's Chairman and CEO, Dennis Mathew; and CFO, Marc Sirota, who together will take you through the presentation and then be available for questions. As today's presentation may contain forward-looking statements, please carefully review the section titled Forward-Looking Statements on Slide 2.

Now turning over to Dennis to begin.

Dennis Mathew
CEO & Chairman

Thank you, Sarah. Good morning, and thank you all for joining us today. Throughout today's presentation, we will discuss the progress we have made, the challenges facing our business and most importantly, how we are responding with urgency and discipline to ensure we continue to strengthen our business for the long term.

I want to start by recognizing where we stand today and the work that still lies ahead. Over the past 3 years since stepping into the CEO role, we've been executing a comprehensive transformation aimed at stabilizing the business, driving operational discipline and slowing declines to position us for future growth. Our financial performance is starting to reflect our operational

Recommended For You

Key Takeaways Trimble's Q3 EPS of $0.81 beat estimates and rose 15.7% year over year on higher revenues.
AECO and Field Systems segments delivered strong organic growth and margin expansion.
Trimble guided for higher Q4 and 2025 earnings, with ARR and revenue growth targets through 2027.

Trimble (TRMB - Free Report) reported third-quarter 2025 non-GAAP earnings of 81 cents per share, which surpassed the Zacks Consensus Estimate by 12.5% and increased 15.7% on a year-over-year basis.

Revenues of $901.2 million beat the Zacks Consensus Estimate by 3.41% and increased 3% year over year (up 10% on an organic basis). Organic growth benefited from strong revenues from the AECO (Architecture, Engineering, Construction, and Owners) segment and Field Systems with Transportation & Logistics continued to grow in a challenging freight market.

Product revenues (33.6% to total revenues) totaled $302.5 million, down 1.7% on a year-over-year basis. Subscription and services revenues (66.4% of total revenues) increased 5.4% year over year to $598.7 million.

Annualized Recurring Revenues (ARR) of $2.31 billion increased 6% on a year-over-year basis (up 14% on an organic basis).

TRMB Q3 Top-line DetailsThe AECO (Architecture, Engineering, Construction, and Owners) segment revenues (39.8% of total revenues) were $358.5 million, up 17.2% year over year. The AECO segment delivered 17% year-over-year organic growth in ARR.

Field Systems revenues (45.4% of total revenues) of $408.7 million increased 8% year over year on an organic basis and 9.1% on a reported basis. The segment saw 18% organic ARR growth in the reported quarter.

Transportation & Logistics (T&L) revenues (14.9% of total revenues) of $134 million declined 31.4% year over year. The segment registered 7% adjusted organic ARR growth.

TRMB’s Q3 Operating DetailsIn the third quarter of 2025, non-GAAP gross margin was 71.2%, expanding 280 basis points (bps) year over year.

Adjusted EBITDA was $269.4 million with adjusted EBITDA margin of 29.9%, up 160 bps year over year.

On a non-GAAP basis, operating expenses accounted for 43% of revenues, up 20 bps year over year.

Non-GAAP operating margin was 28.2%, which expanded 250 bps year over year.

AECO operating margin of 31.8% expanded 270 bps year over year. Field Systems operating margin expanded 40 bps year over year to 33.4%. T&L operating margin expanded 10 bps year over year to 25.8% in the reported quarter.

TRMB’s Balance Sheet DetailsAt the end of third-quarter 2025, cash and cash equivalents were $232.7 million, down from $265.9 million at the end of second-quarter 2025.

Total debt was $1.39 billion at the end of the third quarter compared with $1.51 billion at the second-quarter end.

The company bought shares worth $50 million in the reported quarter. TRMB currently has $273 million under its current repurchase authorization.

TRMB Offers Positive GuidanceFor the fourth quarter of 2025, Trimble expects revenues to be in the range of $927-$967 million. The company expects non-GAAP earnings to be in the band of 91-99 cents per share.

For 2025, Trimble expects revenues to be between $3.545 billion and $3.585 billion. The company expects 2025 non-GAAP earnings to be in the range of $3.04-$3.12 per share.

For 2026, Trimble expects revenues to be in the mid- to-high single-digit range. For 2027, Trimble currently expects $3 billion in ARR, $4 billion in revenues and 30% EBITDA.

Zacks Rank & Other Stocks to ConsiderCurrently, Trimble carries a Zacks Rank #2 (Buy).

Crane Company (CR - Free Report) , Karat Packaging (KRT - Free Report) , and Hubbell (HUBB - Free Report) are stocks worth considering in the broader Zacks Industrial Products sector. Each of the three stocks has a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

 Long-term earnings growth rate for Crane Company, Karat Packaging, and Hubbell is pegged at 14.6%, 12.1%, and 10%, respectively.

 Shares of Crane Company and Hubbell have appreciated 25.9% and 11.8%, year to date, respectively, while Karat Packaging dropped 16.2%.

Key Takeaways RDDT's Q3 ad revenue jumped 74% to $549M, driven by higher advertiser count and deeper investments.
SNAP's ad revenue rose 5% to $1.32B, fueled by Direct Response growth and strong AR engagement.
RDDT's 2025 earnings estimate rose 25.6%, while SNAP's fell amid weaker brand ad demand and competition.

Reddit (RDDT - Free Report) and Snap (SNAP - Free Report) are leading social media platforms that monetize user engagement through digital advertising. While RDDT is an emerging social media platform, gaining traction with community-driven advertising, Snap focuses on visual messaging, AR experiences and creator content.

Per the Grand View Research report, the global digital advertising market size was valued at $488.4 million in 2024 and is expected to reach $1,164.25 million by 2030, registering a CAGR of 15.4% from 2025 to 2030. Both Reddit and Snap are expected to benefit from this rapid growth pace.

RDDT or SNAP — Which of these Social Media stocks has the greater upside potential? Let’s find out.

The Case for RDDT StockReddit is benefiting from strong user engagement, including rising daily and weekly active users, gains in Average Revenue Per User (ARPU), and the expansion of advertiser tools such as DPA, Reddit Pixel and CAPI.

In the third quarter of 2025, Advertising revenues surged 74% year over year to $549 million, driven by both existing advertisers deepening their investments and a 75% rise in the active advertiser count.  This growth highlights Reddit’s ability to attract advertisers across large, mid-market, and small-to-medium-sized businesses.

Reddit’s expanding portfolio has been a major growth driver. In the third quarter of 2025, ARPU grew 41% year over year to $5.04, indicating that portfolio expansions are driving higher monetization per user.

RDDT is also expanding search-led engagement through Reddit Answers. In the third quarter of 2025, over 75 million people searched on Reddit weekly, showcasing the growing popularity of this feature. The company has integrated Reddit Answers into its core search functionality, increasing visibility across conversations and expanding its reach to non-English languages, including Spanish, German, Italian, French, and Portuguese.

The Case for SNAP StockSnap is benefiting from strong revenue growth driven by improved advertising demand and the expansion of direct revenue streams. In the third quarter of 2025, Advertising revenues rose 5% year over year to $1.32 billion, driven primarily by growth in Direct Response (DR) advertising revenue, which increased 8% year over year. Growth in DR advertising revenue was primarily driven by strong demand for Pixel Purchase and App Purchase optimizations.

Snapchat has reached a milestone of more than 477 million daily active users, increasing 8% year over year, and monthly active users increased 7% year over year to 943 million in the third quarter of 2025. This growth was driven by the steady adoption of Augmented Reality Lenses, Spotlight, and AI chatbots, which have enhanced user engagement and creativity on the platform.

Snap is also benefiting from increased engagement with its content and augmented reality (AR) features. In the third quarter of 2025, AR engagement remains strong, with more than 8 billion daily uses of AR lenses and 350 million daily active users engaging with AR experiences.  New AI-powered lenses, such as the Imagine Lens, have further enhanced user creativity and interaction.

Snapchat’s partnership with Perplexity has been noteworthy. The company recently announced a partnership with Perplexity to integrate its AI-powered answer engine directly into the app’s Chat interface. Starting in early 2026, Snapchat’s nearly 1 billion monthly users will be able to ask questions and get verified, conversational answers powered by Perplexity. This marks Snap’s first major step toward making Snapchat a center for trusted AI-driven discovery and learning.

Price Performance and Valuation of RDDT and SNAPIn the year-to-date period, shares of Reddit gained 20.1% outperforming SNAP, which has plunged 32.2%. The outperformance in Reddit can be attributed to strong ad revenue growth, driven by improved targeting, performance tools, global expansion and increased engagement through search-led initiatives, such as Reddit Answers.

Despite SNAP’s expanding portfolio and partnerships, the company is suffering from continued weakness in brand advertising revenues. Stiff competition has also remained a concern.

RDDT and SNAP Stock Performance
Image Source: Zacks Investment Research

Valuation-wise, RDDT and SNAP shares are currently overvalued, as suggested by a Value Score of F.

In terms of the forward 12-month Price/Sales, RDDT shares are trading at 13.4X, which is higher than SNAP’s 1.92X.

RDDT and SNAP Valuation
Image Source: Zacks Investment Research

How Do Earnings Estimates Compare for RDDT & SNAP?The Zacks Consensus Estimate for RDDT’s 2025 earnings is pegged at $2.35 per share, which has increased 25.6% over the past 30 days, indicating a 170.57% year-over-year rise.

The Zacks Consensus Estimate for SNAP’s 2025 earnings is pegged at 25 cents per share, which has decreased by a penny over the past 30 days, indicating a 13.79% decline year over year.

ConclusionWhile both Reddit and SNAP stand to benefit from the expanding digital advertising market, Reddit offers greater upside potential due to its expanding advertising business and clientele, and an improved user experience with upgraded search and discovery features.

While SNAP stands to gain from digital ad market growth and its AR innovations, the company continues to struggle with weak brand advertising and intense competition. It’s slowing earnings momentum further limits its upside potential.

Currently, Reddit sports a Zacks Rank #1 (Strong Buy), making the stock a stronger pick than Snap, which has a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank stocks here.

Q3: 2025-11-05 Earnings SummaryEPS of $1.37 beats by $0.02

 |

Revenue of

$8.09B

(14.16% Y/Y)

beats by $114.97M

Nutrien Ltd. (NTR:CA) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST

Company Participants

Jeff Holzman - Vice President of Investor Relations
Kenneth Seitz - President, CEO & Director
Mark Thompson - Executive VP & CFO
Jeffrey Tarsi - Executive VP & President of Global Retail

Conference Call Participants

Andrew Wong - RBC Capital Markets, Research Division
Ben Isaacson - Scotiabank Global Banking and Markets, Research Division
Hamir Patel - CIBC Capital Markets, Research Division
Joel Jackson - BMO Capital Markets Equity Research
Christopher Parkinson - Wolfe Research, LLC
Vincent Andrews - Morgan Stanley, Research Division
Steven Hansen - Raymond James Ltd., Research Division
Kristen Owen - Oppenheimer & Co. Inc., Research Division
Salvator Tiano - BofA Securities, Research Division
Jeffrey Zekauskas - JPMorgan Chase & Co, Research Division
Edlain Rodriguez - Mizuho Securities USA LLC, Research Division
Michael Doumet - National Bank Financial, Inc., Research Division
Benjamin Theurer - Barclays Bank PLC, Research Division
Lucas Beaumont - UBS Investment Bank, Research Division
Suk Lee - Goldman Sachs Group, Inc., Research Division

Presentation

Operator

Greetings, and welcome to Nutrien's 2025 Third Quarter Earnings Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference call over to Jeff Holzman, Senior Vice President of Investor Relations and FP&A.

Jeff Holzman
Vice President of Investor Relations

Thank you, operator. Good morning, and welcome to Nutrien's Third Quarter 2025 Earnings Call. As we conduct this call, various statements that we make about future expectations, plans and prospects contain forward-looking information. Certain assumptions were applied in making these conclusions and forecasts.

Therefore, actual results could differ materially from those contained in our forward-looking information. Additional information about these factors and assumptions is contained in our quarterly report to shareholders as well as our most recent annual report, MD&A and annual information form.

I will now turn the call over

Recommended For You

Q3: 2025-11-05 Earnings SummaryEPS of $1.52 beats by $0.13

 |

Revenue of

$333.10M

(-11.62% Y/Y)

misses by $27.33M

Ingevity Corporation (NGVT) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST

Company Participants

John Nypaver - VP of Investor Relations & Treasurer
David Li - President, CEO & Director
Mary Hall - Executive VP & CFO
Phillip Platt - Senior VP of Finance & Chief Accounting Officer

Conference Call Participants

Jonathan Tanwanteng - CJS Securities, Inc.
Daniel Rizzo - Jefferies LLC, Research Division
John McNulty - BMO Capital Markets Equity Research

Presentation

Operator

Hello, and welcome to today's Ingevity Third Quarter 2025 Earnings Call and Webcast. My name is Bailey, and I will be your moderator for today. [Operator Instructions]

I'd now like to pass the conference over to John Nypaver. So please go ahead when you're ready.

John Nypaver
VP of Investor Relations & Treasurer

Thank you, Bailey. Good morning, and welcome to Ingevity's Third Quarter 2025 Earnings Call. Earlier this morning, we posted a presentation on our investor site that you can use to follow today's discussion. It can be found on ir.ingevity.com under Events and Presentations.

Also throughout this call, we may refer to non-GAAP financial measures, which are intended to supplement, not substitute for comparable GAAP measures. For example, we are presenting the pending divestiture of our Industrial Specialties business for the first time within discontinued operations. In the appendix to our slides, we provide details that reconcile the total operations. Definitions of these non-GAAP financial measures and reconciliations to comparable GAAP measures are included in our earnings release and are also in our most recent Form 10-K.

We may also make forward-looking statements regarding future events and future financial performance of the company during this call, and we caution you that these statements are just projections and actual results or events may differ materially from those projections as further described in our earnings release.

Our agenda

Recommended For You

Mineros S.A. (OTCPK:MNSAF) Q3 2025 Earnings Call November 6, 2025 9:00 AM EST

Company Participants

David Splett - Chief Financial Officer
David Londono - President & CEO
Santiago Cardona Munera
Inivaldo Diaz

Conference Call Participants

Justin Chan - SCP Resource Finance LP, Research Division
Ben Pirie - Atrium Research Corporation

Presentation

Operator

Good morning. Welcome to Mineros Financial and Operating Results for the Third Quarter of 2025. My name is Juan Camilo and I am the Investor Relations -- Original language will be Spanish. However, if you wish to listen to English, please follow these steps. First, the box that says English. Then to avoid listening to both languages at the same time, identify the box that says media players and click on mute. [Foreign Language] Please remember that this call may include forward-looking information. Actual results may vary due to inherent risks in mining. Several financial metrics -- are Section 10 our MD&A available David Londono, CEO; David Splett, CFO -- and enter finance CEO; Santiago Cardona is a President Colombia. And so Gavilanes, is [Foreign Language]

Unknown Executive

Gold production stands at 163,000 ounces for the first 9 months of the year. This represents a 2.5% increase compared with the 159,000 ounces reported for the same period in 2024. We had a record net income, which reached 50 million for the third quarter and accumulated net income year-to-date of $136 million. We generated positive free cash flow of $62 million in the third quarter and a total of $106 million in net free cash flow for the first 9 of 2025. We concluded to the share buyback program that was approved earlier this year by the shareholders' general assembly and subsequently by the Board of Directors.

The company repurchased a total of 3.9 million shares at a price of

Recommended For You

Gogo Inc. (GOGO) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST

Company Participants

William Davis - Vice President of Investor Relations
Christopher Moore - CEO & Director
Zachary Cotner - Executive VP & CFO

Conference Call Participants

Scott Searle - ROTH Capital Partners, LLC, Research Division
Justin Lang - Morgan Stanley, Research Division

Presentation

Operator

Hello, and thank you for standing by. Welcome to Gogo Third Quarter 2025 Earnings Conference Call. [Operator Instructions]

I would now like to hand the conference over to William Davis. You may begin.

William Davis
Vice President of Investor Relations

Thank you, and good morning, everyone. Welcome to Gogo's Third Quarter 2025 Earnings Conference Call. Joining me today to discuss our results are Chris Moore, CEO; and Zach Cotner, our CFO.

Before we get started, I would like to take this opportunity to remind you that during the course of this call, we may make forward-looking statements regarding future events and the future performance of the company. We caution you to consider the risk factors that could cause actual results to differ materially from those in the forward-looking statements on this call.

Those risk factors are described in our earnings release filed this morning and in a more fully detailed note under risk factors filed in our annual report on 10-K and 10-Q and other documents that we have filed with the SEC. In addition, please note that the date of this conference call is November 6, 2025. Any forward-looking statements that we make today are based on assumptions as of this date, and we undertake no obligation to update these statements as a result of more information or future events. During this call, we'll present both GAAP and non-GAAP financial measures. We have included a reconciliation and explanation of adjustments and other considerations of our non-GAAP measures to the most comparable

Recommended For You

The Needham, Mass.-based household goods company has become a consumer favorite

Key Takeaways PacBio's Q3 loss per share narrowed to 12 cents, topping earnings estimates despite lower sales.Revenues fell 3.8% year over year to $38.4M, hurt by weaker instrument shipments and pricing.Consumables and service revenues rose in double digits, boosting margins and trimming operating loss.
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, delivered an adjusted loss per share of 12 cents in third-quarter 2025, narrower than the year-ago adjusted loss of 17 cents per share. The adjusted loss per share topped the Zacks Consensus Estimate by 25%.

The company’s GAAP loss per share was 13 cents in the quarter compared with the year-ago period’s loss of 22 cents.

PacBio’s Revenues in DetailPacBio registered total revenues of $38.4 million in the third quarter, down 3.8% year over year. The figure missed the Zacks Consensus Estimate by 3.5%.

Shares of this company have lost 12.8% in today’s pre-market trading. The company’s shares have gained 4.6% in the year-to-date period against the industry’s decline of 0.1%. The broader S&P 500 Index has increased 16.6% in the same time frame.

PACB’s Geographical AnalysisPacBio’s revenues from the Americas were $18.1 million, down 10% year over year. The decline wasprimarily due to continued caution in academic capital spending, which weighed heavily on demand for Revio systems. Management highlighted that procurement cycles remain elongated due to a challenging funding environment for academic and government customers dependent on NIH and other public budgets. The company also noted that there was no meaningful end-of-government-year budget, further limiting system purchases, though Vega platform traction improved modestly.

In the Asia-Pacific region, PacBio recorded revenues of $9.6 million, reflecting a 11% decrease year over year. The decline wasmainly due to fewer Revio placements and lower-than-expected ASPs. Per management, although PACB met its regional revenue forecast, instrument sales were pressured by pricing concessions, offset somewhat by stronger-than-expected consumables usage and high pull-through rates at major customers. The funding environment remains challenging in the region, contributing to weaker capital demand even as China outperformed expectations within APAC.

The Europe, the Middle East and Africa (EMEA) region registered revenues of $10.7 million, which improved 18% year over year. This is supported by roughly 50% growth in consumables, driven by higher utilization and an expanding installed base, particularly among commercial and clinically focused customers. This strength offset weaker-than-forecast Vega placements due to delayed procurement timelines, allowing the region to remain PACB’s fastest-growing geography in 2025.

PacBio’s Segmental AnalysisTotal Product revenues amounted to $32.6 million, down 7.7% from the year-ago quarter.

Within the Product segment, Instrument revenues were $11.3 million, down 32.7% year over year. This primarily resulted from lower shipments of the Revio system.Instrument revenues in the third quarter of 2025 included 13 Revio sequencing systems and 32 Vega sequencing systems.

PACB ended the quarter with 310 cumulative Revio system shipments.

Consumables revenues for the third quarter of 2025 were $21.3 million, up 15.1% from the prior-year quarter. AnnualizedRevio pull-through per system was $236,000 in the quarter.

Service and other revenues totaled $5.8million, up 25.1% year over year. This was driven by an increase in service contract revenues related to Revio.

Image Source: Zacks Investment Research

PACB’s Margin TrendIn the quarter under review, PacBio’s adjusted gross profit increased 24.3% year over year to $16.2 million. The adjusted gross margin expanded 950 basis points to 42%.

Sales, general and administrative expenses declined 28.9% year over year to $31.1 million. Research and development expenses decreased 10.5% year over year to $22.8 million. Adjusted total operating expenses of $53.9 million decreased 13.6% year over year.

Total operating loss was $38.9 million in the reported quarter compared with the prior-year quarter’s $64.1 million.

PacBio’s Financial PositionPacBio exited the third quarter of 2025 with cash and investmentsof $298.7million compared with $314.7million at the end of the second quarter of 2025.

PACB’s GuidancePacBio has provided its revenue outlook for the fourth quarter of 2025 and revised the outlook for 2025.

Management expects fourth-quarter 2025 revenues to grow 10% compared with the third quarter of 2025 due to higher Revio placements and continuation of consumables strength.The Zacks Consensus Estimate is pegged at $41.9 million.

The company now expects to achieve revenues between $155 millionand $160 million for 2025 compared with the previous guidance of $155 million to $165 million. The Zacks Consensus Estimate is pegged at $158.7 million.

Our TakePacBio exited the third quarter of 2025 with mixed results, where earnings beat and revenues missed their respective Zacks Consensus Estimate. A robust increase in its Service and other revenues, along with Consumables revenues, was encouraging. The expansion of the adjusted gross margin and reduction in total operating loss also bode well.

During the quarter, PacBio advanced its technology portfolio with the unveiling of SPRQ-Nx sequencing chemistry, designed to materially lower the cost of long-read sequencing. The new chemistry enables high-accuracy HiFi whole-genome sequencing for under $300 per genome at scale and supports multi-use SMRT Cells, which could reduce sequencing costs by up to 40%. PacBio also expanded its clinical-research product suite with the launch of the PureTarget portfolio, offering targeted HiFi assays optimized for difficult-to-sequence genes—most notably in carrier screening. The platform supports throughput of up to approximately 100,000 samples per Revio per year, positioning Revio as a strong solution for large-volume clinical workflows.

Regulatory and scientific milestones reinforced PacBio’s growing position in clinical genomics. Its Sequel II CNDx system received Class III Medical Device Registration in China through partner Berry Genomics—the first known clinical-grade long-read sequencer approval globally—enabling clinical adoption beginning with thalassemia testing and expanding to additional single-gene disorders. Meanwhile, new data published by the HiFi Solves EMEA Consortium demonstrated that PacBio HiFi sequencing, coupled with its Paraphase haplotype-based variant-calling tool, successfully identified all known clinically relevant variants in the evaluated population, underscoring the technology’s readiness for precision medicine and next-generation diagnostics.

PacBio also continued to gain traction in population-scale initiatives. The Revio system was selected for the National Institute on Aging’s Long Life Family Study, which plans to sequence up to 7,800 whole genomes and epigenomes to support research in healthy aging and exceptional longevity. In addition, HiFi sequencing was chosen for the Korean Pangenome Reference Project, targeting more than 1,000 genomes to build population-specific reference data and accelerate development of precision diagnostics and therapies. Collectively, these selections highlight increasing confidence in HiFi long-read sequencing for large-scale research and clinical discovery.

PacBio’s Zacks Rank and Stocks to ConsiderPACB currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space that have announced quarterly results are Boston Scientific Corporation (BSX - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Exact Sciences Corporation (EXAS - Free Report) .

Boston Scientific, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outpaced the consensus mark by 1.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Boston Scientific has a long-term estimated growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.4%.

West Pharmaceutical reported third-quarter 2025 adjusted EPS of $1.96, beating the Zacks Consensus Estimate by 17.4%. Revenues of $804.6 million surpassed the Zacks Consensus Estimate by 2.4%. It currently carries a Zacks Rank #2.

West Pharmaceutical has a long-term estimated growth rate of 9.8%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.5%.

Exact Sciences reported third-quarter 2025 adjusted EPS of 24 cents, beating the Zacks Consensus Estimate by 84.6%. Revenues of $850.7 million surpassed the Zacks Consensus Estimate by 4.9%. It currently sports a Zacks Rank #1.

Exact Sciences has a long-term estimated growth rate of 30.1%. EXAS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 352.3%.

Key Takeaways QuidelOrtho's Q3 EPS of $0.80 and revenues of $699.9M beat the consensus estimate.Labs and Immunohematology units delivered solid growth, offsetting weaker respiratory sales.Adjusted operating margin rose 70 bps to 17.1%, driven by lower expenses and improved efficiency.
QuidelOrtho Corporation (QDEL - Free Report) delivered adjusted earnings per share (EPS) of 80 cents in third-quarter 2025 down from the year-earlier EPS of 85 cents. However, the figure surpassed the Zacks Consensus Estimate by 56.9%.

The adjustments include expenses related to the amortization of intangibles, and acquisition and integration costs, among others.

GAAP loss per share for the quarter was $10.78 compared with the year-earlier loss of 30 cents per share.

QDEL’s Revenues in DetailQuidelOrtho registered revenues of $699.9 million in the third quarter of 2025, which decreased 3.8% year over year on a reported basis and 4.6% at constant exchange rate (CER). However, the figure surpassed the Zacks Consensus Estimate by 5.3%.

In the third quarter, Respiratory revenues were $112.3 million (down 32.1% on a reported basis and 32.2% at CER), while Non-Respiratory revenues were $587.6 million (up 4.6% on a reported basis and 3.5% at CER).

QuidelOrtho’s Business Units in DetailQuidelOrtho derives revenues from five business units — Labs, Immunohematology, Donor Screening, Point of Care and Molecular Diagnostics. As a result of the wind-down of the U.S. Donor Screening portfolio, the previously reported Transfusion Medicine business unit is now presented in its two product categories — Immunohematology and Donor Screening.

In the third quarter, Labs revenues were $373.8 million, up 5% on a reported basis and 4.4% at CER.

Immunohematologyrevenues were $142 million in the third quarter, up 7.7% and 5.2% on a reported basis and at CER, respectively.

Donor Screening revenues were $14.7 million in the third quarter, down 47.3% and 47.2% on a reported basis and at CER, respectively.

Point of Care revenues amounted to $164.6 million in the third quarter, reflecting a decline of 20%on a reported basis and 20.3% at CER.

Molecular Diagnosticsrevenues totaled $4.8million in the third quarter, down 14.3% and 14.8% on a reported basis and at CER, respectively.

QDEL’s Geographical DistributionGeographically, QuidelOrtho derives revenues from North America, Europe, the Middle East and Africa (EMEA), China and Other regions (which include Latin America, Japan and other Asia-Pacific markets).

Revenues from North Americaamounted to $381.4million, reflecting a decline of 12.6% and 12.5% on a reported basis and at CER, respectively.

EMEA revenues amounted to $91.8million, reflecting an increase of 9.3% on a reported basis and 2.4% at CER.

Revenues from China amounted to $84.6million, reflecting an increase of 5.2% on a reported basis and 4.8% at CER.

Revenues from Other regions amounted to $142.1million, reflecting an uptick of 12.3% on a reported basis and 12% at CER.

QuidelOrtho’s Margin TrendIn the quarter under review, QuidelOrtho’s adjusted gross profit declined 4.6% year over year to $341 million. The adjusted gross margin contracted 50 basis points (bps) to 48.7%.

Adjusted selling, marketing and administrative expenses fell 0.7% year over year to $175.6 million. Adjusted research and development expenses declined 25.9% year over year to $40.9 million. Adjusted operating expenses of $216.5 million decreased 6.7% year over year.

Adjusted operating profit totaled $119.6 million, reflecting a 0.1% improvement from the prior-year quarter’s level. Adjusted operating margin in the third quarter expanded 70 bps to 17.1%.

QDEL’s Financial PositionQuidelOrtho exited the third quarter of 2025 with cash and cash equivalents of $98.1 million compared with $151.7 million at the second-quarter end. Total debt (including short-term debt) at the end of third-quarter 2025 was $2.66 billion compared with $2.61 billion at the second-quarter end.

Cumulative net cash used in operating activities at the end of the third quarter was $26.7 million, against net cash provided by operating activities of $19.3 million a year ago.

QuidelOrtho’s GuidanceQuidelOrtho has reiterated its financial outlook for 2025.

Total revenues are expected to lie in the range of$2.68 billion-$2.74 billion billion. The Zacks Consensus Estimate is pegged at $2.71 billion.

For the full year, QuidelOrtho projects stable growth across most business lines, with strength in its Labs and Immunohematology businesses. In China, full-year growth is expected to be in the mid-single digits. This optimism is supported by strong performance in clinical chemistry and immunohematology, with limited impact from the country’s volume-based procurement policies.

Within theRespiratory revenues for the full year, COVID-19 revenues are expected to be in the range of $70-$100 million for 2025, assuming no government contract revenue.

Adjusted EPS is expected to be between $2.00 and $2.15. The Zacks Consensus Estimate is pegged at $2.28.

Our TakeQuidelOrtho ended the third quarter of 2025 with better-than-expected results, where both earnings and revenues beat their respective Zacks Consensus Estimate. The company registered robust revenues from its Labs and Immunohematology business units and EMEA, China and Other regions, which were encouraging. The expansion of margins bodes well.

However, continued decline in respiratory revenues hurt the overall topline. Donor Screening, Point of Care and Molecular Diagnostics business units witnessed a decrease in revenues. A decline in year-over-over bottom line does not bode well.

QDEL’s Zacks Rank and Key PicksQDEL currently carries a Zacks Rank #5 (Strong Sell).

Some better-ranked stocks in the broader medical space that have announced quarterly results are Boston Scientific Corporation (BSX - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Exact Sciences Corporation (EXAS - Free Report) .

Boston Scientific, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outpaced the consensus mark by 1.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Boston Scientific has a long-term estimated growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.4%.

West Pharmaceutical reported third-quarter 2025 adjusted EPS of $1.96, beating the Zacks Consensus Estimate by 17.4%. Revenues of $804.6 million surpassed the Zacks Consensus Estimate by 2.4%. It currently carries a Zacks Rank #2.

West Pharmaceutical has a long-term estimated growth rate of 9.8%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.5%.

Exact Sciences reported third-quarter 2025 adjusted EPS of 24 cents, beating the Zacks Consensus Estimate by 84.6%. Revenues of $850.7 million surpassed the Zacks Consensus Estimate by 4.9%. It currently sports a Zacks Rank #1.

Exact Sciences has a long-term estimated growth rate of 30.1%. EXAS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 352.3%.

Hexagon Composites ASA (OTCPK:HXGCF) Q3 2025 Earnings Call November 6, 2025 2:30 AM EST

Company Participants

Berit-Cathrin Hoyvik - Senior Director of Communications
Philipp Schramm - Chief Executive Officer
David Bandele - Chief Financial Officer

Presentation

Berit-Cathrin Hoyvik
Senior Director of Communications

Good morning, everyone, and welcome to Hexagon Composites Q3 presentation. My name is Berit-Cathrin Hoyvik, and I'll be moderating today's presentation. Joining me in the studio today is our CEO, Philipp Schramm; and CFO, David Bandele. They will take you through our company update, financials and outlook before we wrap up with a Q&A session. And with that, I'll hand the word over to Philipp.

Philipp Schramm
Chief Executive Officer

Thank you. Good morning, everyone, and thank you for joining us for our Q3 presentation. Let's start with a high-level summary of the third quarter this year. The macroeconomic uncertainty continues to negatively weigh on our business and our core markets are in a cyclical downturn in combination with an unprecedented macro environment. This has significantly affected our volumes and our profitability this quarter, and our Q3 results are weak with group revenues, which came in with NOK 538 million and led to an EBITDA of negative NOK 54 million. August contributed to the majority of our Q3 EBITDA loss.

With our banking partners, we decided to initiate an equity raise to improve our balance sheet, and we have raised NOK 590 million. In September, we launched a group-wide cost savings program targeted at reducing our cost base, improving our EBITDA breakeven point and securing our liquidity.

I will come back to the results and details of this program in more detail shortly. In addition, we remain focused on executing the strategic steps that will drive the adoption of natural gas in North America and in Europe.

So let's take

Recommended For You

MariMed Inc. (OTCQX:MRMD) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST

Company Participants

Anna Massanari
Jon Levine - Co-Founder, CEO, President, Secretary, Treasurer & Director
Ryan Crandall - Chief Commercial Officer
Mario Pinho - Chief Financial Officer

Conference Call Participants

Andrew Semple - Ventum Financial Corp., Research Division
Joseph Gomes - NOBLE Capital Markets, Inc., Research Division
Pablo Zuanic - Zuanic & Associates

Presentation

Operator

Good morning. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the MariMed Inc. Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] I would now like to turn the call over to Mr. Howard Schacter, Chief Communications Officer, to begin the conference.

Anna Massanari

Hello, and good morning, everyone. My name is Anna Massanari, Associate Director of Trade and Field Marketing at MariMed. I'm very proud of the contributions my team has made in supporting sales, market share expansion and strengthening industry relationships for the company. We literally hit the ground running every day visiting wholesale accounts to educate budtenders about our products, engaging with consumers at hundreds of brand pop-ups and representing the company at important trade events.

I'm honored to kick off today's 2025 third quarter earnings call. Joining the call today are Jon Levine, our Chief Executive Officer; Ryan Crandall, our Chief Commercial Officer; and Mario Pinho, our Chief Financial Officer.

This call will be archived on our Investor Relations website and contains forward-looking statements. Actual events or results may differ materially from these forward-looking statements and are subject to various risks and uncertainties.

A discussion of some of these risks is in our Risk Factors sections of our 10-K and 10-Q available on our website. Any forward-looking statements reflect management's expectations as of today. We assume no obligations to update them

Recommended For You

BT Group plc (OTCPK:BTGOF) Q2 2026 Earnings Call November 6, 2025 5:00 AM EST

Company Participants

Allison Kirkby - CEO & Director
Simon Lowth - CFO & Executive Director

Conference Call Participants

David Wright - BofA Securities, Research Division
James Ratzer - New Street Research LLP
Andrew Lee - Goldman Sachs Group, Inc., Research Division
Karen Egan - Enders Analysis Ltd
Joshua Mills - BNP Paribas, Research Division
Max Findlay - Rothschild & Co Redburn, Research Division
Maurice Patrick - Barclays Bank PLC, Research Division
Carl Murdock-Smith - Citigroup Inc., Research Division
Andrew Beale - Arete Research Services LLP
Nicholas Lyall - Joh. Berenberg, Gossler & Co. KG, Research Division

Presentation

Operator

Good morning, and welcome, everyone, to BT Group's results presentation for the half year ended 30th of September 2025. Presenting today is Allison Kirkby, BT Group's Chief Executive; and Simon Lowth, BT Group's CFO. Following the presentation, we'll be having a Q&A session. I would like to make everyone aware that this event is being recorded for replay purposes. Before we start, I'd like to draw your attention to the usual forward-looking statements in our press release and our latest annual report for examples of the factors that could cause actual results to differ from any forward-looking statements we may make. Both the press release and the annual report can be found on our website. With that, I'll now hand over to Allison.

Allison Kirkby
CEO & Director

Hi. Good morning, everyone, and welcome, and thank you for joining us for our half year results. In terms of the presentation this morning, I'm going to start by setting out the progress we've made against our strategic priorities so far this year. Simon will update on the financials, and then we very much look forward to taking your questions after a quick recap from myself. So in summary, it's been another period of solid delivery despite the

Recommended For You

Operator

Welcome to the Twin Vee Powercats Company Third Quarter 2025 Investor Call. As a reminder, this call is being recorded. [Operator Instructions] Your speakers for today's program are President and CEO, Joseph Visconti and Chief Financial Officer, Scott Searles.

Before I turn the call over to Joseph, please remember that certain statements made during this investor call are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements on this call, other than statements of historical facts, including statements regarding the company's future operations and financial position, business strategy and plans and objectives of management for future operations are forward-looking statements.

In some cases, forward-looking statements can be identified by terminologies such as believes, may, estimates, continue, anticipates, intends, should, plan, expects, predict, potential or the negative of these terms or other similar expressions. The company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs.

These forward-looking statements are subject to a number of risks and uncertainties and assumptions described, including those set forth in its filings with the Securities and Exchange Commission, which are available on the company's Investor Relations website at ir.twinvee.com. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur.

Finally, this conference call is being webcast. The webcast will be available at ir.twinvee.com for at least 90 days. Audiocast quality

RKLB's strong launch growth and solid bookings are likely to lift Q3 results, but high costs and rich valuation could test investor patience.

Nexstar Media Group, Inc. (NXST) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST

Company Participants

Perry Sook - Founder, Chairman & CEO
Michael Biard - President & COO
Lee Gliha - Executive VP & CFO

Conference Call Participants

Joseph Jaffoni - JCIR
Daniel Kurnos - The Benchmark Company, LLC, Research Division
Benjamin Soff - Deutsche Bank AG, Research Division
Steven Cahall - Wells Fargo Securities, LLC, Research Division
Craig Huber - Huber Research Partners, LLC
Patrick Sholl - Barrington Research Associates, Inc., Research Division
Aaron Watts - Deutsche Bank AG, Research Division

Presentation

Operator

Good day, and welcome to the Nexstar Media Group's Third Quarter 2025 Conference Call. Today's call is being recorded. I will now turn the conference over to Joe Jaffoni, Investor Relations. Please go ahead, sir.

Joseph Jaffoni
JCIR

Thank you, Kerri, and good morning, everyone. Let me read the safe harbor language, and then we'll get right into the call.

All statements and comments made by management during this conference call other than statements of historical fact, may be deemed forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Nexstar cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those reflected by the forward-looking statements made during this call. For additional details on these risks and uncertainties, please see Nexstar's annual report on Form 10-K for the year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission and Nexstar's subsequent public filings with the SEC.

Nexstar undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. With that, it's my pleasure to turn the conference over to your host, Nexstar Founder, Chairman and CEO, Perry Sook. Perry, please go ahead.

Recommended For You